The COVID-19 Long Haul Foundation

Treatment, Referral & Educational Support for COVID-19 Illnesses & Vaccine Injury

US FDA blocked publication of COVID, shingles vaccine safety studies

By Padmanabhan Ananthan

May 5 (Reuters) – Officials at the U.S. Food and Drug Administration blocked the ​publication of several studies supporting the safety of widely used ‌vaccines against COVID-19 and shingles, a Department of Health and Human Services spokesperson said.

Andrew Nixon, a spokesman for the Department of Health and Human Services, which oversees the ​FDA, said the studies were pulled over concerns about their conclusions.

Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here.

“The ​studies were withdrawn because the authors drew broad conclusions that ⁠were not supported by the underlying data. The FDA acted to ​protect the integrity of its scientific process and ensure that any work associated ​with the agency meets its high standards,” he said in an email to Reuters.

The withdrawal of these studies is the latest attempt by the health regulator and the administration ​to limit access to vaccines, reflecting broader policy changes under U.S. ​Health Secretary Robert F. Kennedy Jr., a staunch critic of vaccines.

The Trump administration has sharply ‌reduced ⁠funding for vaccine research and raised questions about vaccine safety and effectiveness under the tenure of Kennedy, who has introduced sweeping changes across federal health agencies.

In August last year, the U.S. Department of Health and Human Services ​said it would wind ​down nearly $500 million ⁠in mRNA vaccine development, cancelling 22 federal projects overseen by the Biomedical Advanced Research and Development Authority (BARDA), a ​government-backed funding body.

Last June, a Centers for Disease Control and ​Prevention ⁠panel backed by Kennedy voted to remove mercury-based preservative thimerosal from flu shots, despite long-standing clinical evidence of its safety.

British drugmaker GSK (GSK.L), opens new tab markets Shingrix, a vaccine for ⁠shingles, ​a painful viral infection that causes blisters and ​rashes, while Pfizer (PFE.N), opens new tab and Moderna (MRNA.O), opens new tab are the leading makers of COVID-19 vaccines.

Leave a Reply

Your email address will not be published. Required fields are marked *